Author: Hayet Brahmer
Topic: Parkinson’s DBS Innovation
In the ongoing battle against Parkinson’s disease (PD), a progressive neurological disorder that compromises movement and quality of life, technology continues to play a transformative role. One of the most groundbreaking developments in recent years is Medtronic’s Percept Deep Brain Stimulation (DBS) system, which includes the newly FDA-approved Percept RC neurostimulator. This innovative device not only delivers therapeutic stimulation but also captures real-time brain signals—offering hope for a more personalized and effective treatment.
The system involves implanting a small, pacemaker-like device under the skin of the chest. This neurostimulator connects via electrodes to regions in the brain responsible for regulating movement. The device sends mild electrical pulses to these areas, helping regulate abnormal brain activity associated with PD. What sets Percept apart is its integration of BrainSense technology, which records and monitors the brain’s electrical activity (local field potentials or LFPs), even while delivering therapy. This dual functionality represents a significant advancement over traditional DBS systems, which induce stimulation without providing key feedback on brain response. With BrainSense, clinicians can better understand the relationship between a patient’s brain signals and symptoms, fine-tuning stimulation settings based on neural data as needed.
For individuals living with Parkinson’s, symptom fluctuations can make disease management a daily challenge. As the disease progresses, medications may become less effective or even introduce complications. Percept offers a new avenue by enabling clinicians to map brain activity linked to symptoms such as tremor, stiffness, and slowness of movement. By analyzing this data, clinicians can adapt DBS therapy over time, potentially leading to more stable symptom control. For researchers, BrainSense opens the door to a better understanding of Parkinson’s pathology by enabling the study of neural patterns over prolonged periods outside clinical settings.
Medtronic’s latest Percept RC neurostimulator is also notable for its size and longevity. It is the smallest and thinnest dual-channel neurostimulator on the market and offers a rechargeable battery that lasts at least 15 years. The device recharges rapidly—charging from 10% to 90% in under an hour—reducing the burden on patients. Another key feature is MRI compatibility; with many PD patients requiring regular imaging, the Percept system is cleared for use in 1.5T and 3T MRI scans under specific conditions, giving patients access to essential diagnostics without disruption to their current therapies.
With over 25 years of innovation in DBS and more than 175,000 devices implanted globally, Medtronic continues to lead in neuromodulation technologies. The Percept DBS system marks a major step forward in treating Parkinson’s disease—not just by delivering therapy but by empowering physicians with authentic data for personalized care. As research concerning brain sensing evolves, this technology could pave the way toward a more adaptive, responsive future in neurological treatment.
References
Medtronic. “FDA Approves Medtronic Percept™ RC Neurostimulator with Exclusive BrainSense™ Technology.” Medtronic Newsroom, 8 Jan. 2024, https://news.medtronic.com/2024-01-08-FDA-approves-Medtronic-Percept-TM-RC-neurostimulator-with-exclusive-BrainSense-TM-technology.
Medtronic. Medtronic Percept™ PC Neurostimulator with BrainSense™ Technology: Media Kit. Pacific Neuroscience Institute, Dec. 2020, https://www.pacificneuroscienceinstitute.org/movement-disorders/wp-content/uploads/sites/7/2020/12/US-Percept-Media-Kit-US-FY21-FINAL.pdf.
Newmarker, Chris. “Medtronic Wins FDA Nod for ‘Game-Changing’ DBS Device.” MassDevice, 8 Jan. 2024, https://www.massdevice.com/medtronic-wins-fda-nod-for-game-changing-dbs-device/.